Indications for: BASAGLAR
Type 1 diabetes (in adults and children) and type 2 diabetes (in adults).
Limitations of Use:
Not for treating diabetic ketoacidosis.
Adults and Children:
Give by SC inj once daily at same time each day into abdominal area, thigh, or deltoids; rotate inj sites. No pronounced peak, duration over 24hrs. <6yrs: not established. ≥6yrs: individualize; monitor and adjust as needed. Type 1 diabetes: initially ⅓ of total daily insulin dose. Give remainder of the total dose as short- or rapid-acting, premeal insulin. Type 2 diabetes: initially 0.2 Units/kg or up to 10 Units once daily. May need to adjust amount, timing of short- or rapid-acting insulins and doses of any antidiabetics. Switching from another insulin glargine 100 Units/mL product: initial Basaglar dose should be the same as previous insulin glargine 100 Units/mL dose. Switching from once-daily insulin glargine 300 Units/mL: initially 80% of the previous insulin glargine 300 Units/mL dose. Switching from an intermediate- or long-acting insulin regimen (other than insulin glargine 100 Units/mL): may need to change basal insulin dose; and adjust the amount, timing of the short-acting insulins and doses of any antidiabetics. Switching from twice-daily NPH: initially 80% of the previous total NPH dose.
During episodes of hypoglycemia.
Instruct patients on proper administration of insulin, type of insulin, and management of hypoglycemia. Do not reuse or share pens, needles, or syringes between patients, even if the needle is changed. Visual impairment: will need assistance with prefilled pens. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. Increased risk of hyper- or hypoglycemia if changes in physical activity, meal patterns, renal or hepatic function, insulin regimen, administration site, and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Pregnancy. Nursing mothers.
Do not mix or dilute with other insulins. Potentiated by antidiabetic agents, ACEIs, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, salicylates, somatostatin analogs, sulfonamide antibiotics. Antagonized by corticosteroids, isoniazid, niacin, danazol, diuretics, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, glucagon, oral contraceptives, progestogens, atypical antipsychotics, protease inhibitors. Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt signs of hypoglycemia.
Hypoglycemia, allergic reactions, inj site reactions, lipodystrophy, pruritus, rash, edema, weight gain; hypokalemia.
Generic Drug Availability:
KwikPen prefilled pens (3mL)—5